Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. We are a fast-growing company looking for talented individuals to develop our cutting edge technologies and therapeutic products. We are committed to excellence, creativity, teamwork, and open communication.
Elusys is an active member of BioNJ and we regularly participate in scientific and industry meetings to stay current in our exciting field.